EX-10.1
from 10-Q
1 page
(1) Pursuant to Section 3.1.2 of That License Agreement by and Between Zander Therapeutics, Inc. and Regen Biopharma, Inc.(“agreement”) , Zander Is Obligated to Pay to Regen an Annual Non-Refundable Payment of $100,000 on Each Anniversary Date of the Agreement (“Annual Anniversary Fee”) (2) Zander, by Making Payment of $90,000 on or Before February 10, 2018, Shall Have Fully Satisfied Its June 2018 Annual Anniversary Fee Obligation. /S/David Koos David Koos Chairman & CEO Agreed to By: /S/Todd S. Caven Todd S. Caven Chief Financial Officer Regen Biopharma, Inc
12/34/56
EX-10.61
from 10-K
6 pages
This Business Advisory Board Services Agreement (The “Agreement”), Dated June 23, 2017, Is Entered Into Between Zander Therapeutics, Inc., a Nevada Corporation (“The Company), and Brian Devine, an Individual With a Principal Place of Residence California(“candidate”). Whereas, the Company Desires to Retain the Services of Candidate for the Benefit of the Company and Its Stockholders; and Whereas, Candidate Desires to Serve as Chairman of the Company’s Business Advisory Board for the Period of Time and Subject to the Terms and Conditions Set Forth Herein; Now, Therefore, for Consideration and as Set Forth Herein, the Parties Hereto Agree as Follows
12/34/56
